Skip to content

Near-infrared fluorescence molecular image guided hepatocellular carcinoma surgery using GPC-3 targeted fluorophore

Near-infrared fluorescence molecular image guided hepatocellular carcinoma surgery using GPC-3 targeted fluorophore

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046364
Enrollment
Unknown
Registered
2021-05-14
Start date
2021-06-01
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Gold Standard:Pathological results, including H&E staining section microscopy, frozen section microscopy, and immunofluorescence microscopy.
imaging&#32

Sponsors

Institute of Automation, Chinese Academy of Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. The patient meets the criteria of "Primary Liver Cancer Diagnosis and Treatment Standards (2019 Edition)" and is clinically diagnosed as a patient with primary liver cancer; 2. Combine imaging examinations and laboratory tests before surgery to prepare patients for surgical resection of liver cancer (including radical resection and cytoreductive surgery); 3. The liver function before surgical resection is Child-A grade or the liver function is Child-B grade, after treatment such as liver protection, nutritional fluids, etc., can reach Child-A grade; 4. GPC-3 molecular markers are detected as high expression before operation; 5. The patients gender is not limited, the age is 18-60 years, and the life expectancy is >=3 months; 6. Inform the patients in detail of the possible advantages and disadvantages before and after the operation, and the patients and their families voluntarily choose the treatment plan and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to IRDye800 reagent (take a skin test before medication); 2.3 Patients who have participated in other clinical trials within the past month; 3. Those who have been diagnosed with malignant tumors in other parts; 4. Severe heart, lung, kidney, brain and other important organ diseases; 5. The preoperative assessment believes that the patient's whole body and organs are difficult to tolerate open liver cancer resection; 6. Patients deemed unsuitable by the investigator.

Design outcomes

Primary

MeasureTime frame
Hepatocellular carcinoma number of intraoperative in vivo detection.;

Countries

China

Contacts

Public ContactHu Zhenhua

Institute of Automation, Chinese Academy of Sciences

zhenhua.hu@ia.ac.cn+86 13581998316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026